KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Assets: 2009-2024

Historic Non-Current Assets for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $383.4 million.

  • Ionis Pharmaceuticals' Non-Current Assets rose 39.99% to $514.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $514.1 million, marking a year-over-year increase of 39.99%. This contributed to the annual value of $383.4 million for FY2024, which is 10.10% up from last year.
  • Ionis Pharmaceuticals' Non-Current Assets amounted to $383.4 million in FY2024, which was up 10.10% from $348.2 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-Current Assets peaked at $383.4 million during FY2024, and registered a low of $259.0 million during FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $348.2 million (2023), whereas its average is $354.3 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Non-Current Assets tumbled by 49.46% in 2020, and later grew by 24.21% in 2022.
  • Ionis Pharmaceuticals' Non-Current Assets (Yearly) stood at $259.0 million in 2020, then climbed by 2.93% to $266.6 million in 2021, then rose by 24.21% to $331.2 million in 2022, then increased by 5.14% to $348.2 million in 2023, then grew by 10.10% to $383.4 million in 2024.